TMO three-lens brief
Evidence-based stock research on TMO. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 8.5pp over 30 days. · Debt-to-equity of 82.9 — balance-sheet-heavy.
- Underperforming SPY by 8.5pp over 30 days.
- Analyst mean target $639.88 — 36% above current (24 analysts).
- Debt-to-equity of 82.9 — balance-sheet-heavy.
TMO closed at $469.71 (+0.64%) as of 2026-04-25. Market cap: $174.55B. P/E (trailing) 25.8. Positives: analyst mean target $639.88 — 36% above current (24 analysts).. Concerns: underperforming SPY by 8.5pp over 30 days.; debt-to-equity of 82.9 — balance-sheet-heavy.. Last quarter: Revenue $11.01B, net income $1.65B, free cash flow $5.51B.
Why three lenses on TMO, not one.
A single reasoning model has blind spots it doesn’t know about. We examine TMOacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/TMO" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath TMO brief"></iframe>